Nucifora G, Laricchia-Robbio L and Senyuk V: EVI1 and hematopoietic disorders: History and perspectives. Gene. 368:1–11. 2006. View Article : Google Scholar

Haladyna JN, Yamauchi T, Neff T and Bernt KM: Epigenetic modifiers in normal and malignant hematopoiesis. Epigenomics. 7:301–320. 2015. View Article : Google Scholar : PubMed/NCBI

Yamazaki H, Suzuki M, Otsuki A, Shimizu R, Bresnick EH, Engel JD and Yamamoto M: A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI-1 expression. Cancer Cell. 25:415–427. 2014. View Article : Google Scholar : PubMed/NCBI

Ney Garcia DR, Liehr T, Emerenciano M, Meyer C, Marschalek R, Pombo-de-Oliveira MS, Ribeiro RC, Poirot Land MG and Macedo Silva ML: Molecular studies reveal a MLL-MLLT3 gene fusion displaced in a case of childhood acute lymphoblastic leukemia with complex karyotype. Cancer Genet. 208:143–147. 2015. View Article : Google Scholar : PubMed/NCBI

De Braekeleer M, Le Bris MJ, De Braekeleer E, Basinko A, Morel F and Douet-Guilbert N: 3q26/EVI-1 rearrangements in myeloid hemopathies: A cytogenetic review. Future Oncol. 11:1675–1686. 2015. View Article : Google Scholar

Su G, Lian X, Tan D, Tao H, Liu H, Chen S, Yin H, Wu D and Yin B: Aberrant expression of ecotropic viral integration site-1 in acute myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma. 56:472–479. 2015. View Article : Google Scholar

Glass C, Wilson M, Gonzalez R, Zhang Y and Perkins AS: The role of EVI1 in myeloid malignancies. Blood Cells Mol Dis. 53:67–76. 2014. View Article : Google Scholar : PubMed/NCBI

Koos B, Bender S, Witt H, Mertsch S, Felsberg J, Beschorner R, Korshunov A, Riesmeier B, Pfister S, Paulus W, et al: The transcription factor evi-1 is overexpressed, promotes proliferation, and is prognostically unfavorable in infratentorial ependymomas. Clin Cancer Res. 17:3631–3637. 2011. View Article : Google Scholar : PubMed/NCBI

Jazaeri AA, Ferriss JS, Bryant JL, Dalton MS and Dutta A: Evaluation of EVI-1 and EVI-1s (Delta324) as potential therapeutic targets in ovarian cancer. Gynecol Oncol. 118:189–195. 2010. View Article : Google Scholar : PubMed/NCBI

Balgobind BV, Lugthart S, Hollink IH, Arentsen-Peters ST, van Wering ER, de Graaf SS, Reinhardt D, Creutzig U, Kaspers GJ, de Bont ES, et al: EVI-1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia. 24:942–949. 2010. View Article : Google Scholar : PubMed/NCBI

Yasui K, Konishi C, Gen Y, Endo M, Dohi O, Tomie A, Kitaichi T, Yamada N, Iwai N, Nishikawa T, et al: EVI-1, a target gene for amplification at 3q26, antagonizes transforming growth factor-β-mediated growth inhibition in hepatocellular carcinoma. Cancer Sci. 106:929–937. 2015. View Article : Google Scholar : PubMed/NCBI

Bindels EMJ, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV, Rombouts E, Armstrong SA, Taskesen E, Haanstra JR, et al: EVI-1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood. 119:5838–5849. 2012. View Article : Google Scholar : PubMed/NCBI

Mucenski ML, Taylor BA, Ihle JN, Hartley JW, Morse HC III, Jenkins NA and Copeland NG: Identification of a common ecotropic viral integration site, EVI-1, in the DNA of AKXD murine myeloid tumors. Mol Cell Biol. 8:301–308. 1988. View Article : Google Scholar : PubMed/NCBI

Xu K, Wang L and Hao Y: Advances in the study of EVI-1 and mds1 genes. Zhonghua Xue Ye Xue Za Zhi. 20:331–333. 1999.(In Chinese).

Aytekin M, Vinatzer U, Musteanu M, Raynaud S and Wieser R: Regulation of the expression of the oncogene EVI-1 through the use of alternative mRNA 5′-ends. Gene. 356:160–168. 2005. View Article : Google Scholar : PubMed/NCBI

Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD and Nucifora G: Intergenic splicing of MDS1 and EVI-1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci USA. 93:1642–1647. 1996. View Article : Google Scholar

Soderholm J, Kobayashi H, Mathieu C, Rowley JD and Nucifora G: The leukemia-associated gene MDS1/EVI-1 is a new type of GATA-binding transactivator. Leukemia. 11:352–358. 1997. View Article : Google Scholar : PubMed/NCBI

Delwel R, Funabiki T, Kreider BL, Morishita K and Ihle JN: Four of the seven zinc fingers of the EVI-1 myeloid-transforming gene are required for sequence-specific binding to GA(C/T) AAGA(T/C)AAGATAA. Mol Cell Biol. 13:4291–4300. 1993. View Article : Google Scholar : PubMed/NCBI

Funabiki T, Kreider BL and Ihle JN: The carboxyl domain of zinc fingers of the EVI-1 myeloid transforming gene binds a consensus sequence of GAAGATGAG. Oncogene. 9:1575–1581. 1994.PubMed/NCBI

Lopingco MC and Perkins AS: Molecular analysis of EVI-1, a zinc finger oncogene involved in myeloid leukemia. Curr Top Microbiol Immunol. 211:211–222. 1996.

Saito Y and Morishita K: Maintenance of leukemic and normal hematopoietic stem cells in bone marrow niches by EVI-1-regulated GPR56. Rinsho Ketsueki. 56:375–383. 2015.(In Japanese). PubMed/NCBI

Fukuda S, Hoggatt J, Singh P, Abe M, Speth JM, Hu P, Conway EM, Nucifora G, Yamaguchi S and Pelus LM: Survivin modulates genes with divergent molecular functions and regulates proliferation of hematopoietic stem cells through EVI-1. Leukemia. 29:433–440. 2015. View Article : Google Scholar

Goyama S, Yamamoto G, Shimabe M, Sato T, Ichikawa M, Ogawa S, Chiba S and Kurokawa M: EVI-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell. 3:207–220. 2008. View Article : Google Scholar : PubMed/NCBI

Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A, Mucenski ML, Suda T and Morishita K: Oncogenic transcription factor EVI-1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J. 24:1976–1987. 2005. View Article : Google Scholar : PubMed/NCBI

Matsugi T, Kreider BL, Delwel R, Cleveland JL, Askew DS and Ihle JN: The EVI-1 zinc finger myeloid transforming protein binds to genomic fragments containing (GATA)n sequences. Oncogene. 11:191–198. 1995.PubMed/NCBI

Kreider BL, Orkin SH and Ihle JN: Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the EVI-1 myeloid-transforming gene. Proc Natl Acad Sci USA. 90:6454–6458. 1993. View Article : Google Scholar : PubMed/NCBI

Laricchia-Robbio L, Fazzina R, Li D, Rinaldi CR, Sinha KK, Chakraborty S and Nucifora G: Point mutations in two EVI-1 Zn fingers abolish EVI-1-GATA1 interaction and allow erythroid differentiation of murine bone marrow cells. Mol Cell Biol. 26:7658–7666. 2006. View Article : Google Scholar : PubMed/NCBI

Louz D, van den Broek M, Verbakel S, Vankan Y, van Lom K, Joosten M, Meijer D, Löwenberg B and Delwel R: Erythroid defects and increased retrovirally-induced tumor formation in EVI-1 transgenic mice. Leukemia. 14:1876–1884. 2000. View Article : Google Scholar : PubMed/NCBI

Morishita K, Parganas E, Matsugi T and Ihle JN: Expression of the EVI-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor. Mol Cell Biol. 12:183–189. 1992. View Article : Google Scholar : PubMed/NCBI

Boyd KE, Xiao YY, Fan K, Poholek A, Copeland NG, Jenkins NA and Perkins AS: Sox4 cooperates with EVI-1 in AKXD-23 myeloid tumors via transactivation of proviral LTR. Blood. 107:733–741. 2006. View Article : Google Scholar

Laricchia-Robbio L, Premanand K, Rinaldi CR and Nucifora G: EVI-1 Impairs myelopoiesis by deregulation of PU.1 function. Cancer Res. 69:1633–1642. 2009. View Article : Google Scholar : PubMed/NCBI

Shimizu S, Nagasawa T, Katoh O, Komatsu N, Yokota J and Morishita K: EVI-1 is expressed in megakaryocyte cell lineage and enforced expression of EVI-1 in UT-7/GM cells induces megakaryocyte differentiation. Biochem Biophys Res Commun. 292:609–616. 2002. View Article : Google Scholar : PubMed/NCBI

Kilbey A, Alzuherri H, McColl J, Calés C, Frampton J and Bartholomew C: The EVI-1 proto-oncoprotein blocks endomitosis in megakaryocytes by inhibiting sustained cyclin-dependent kinase 2 catalytic activity. Br J Haematol. 130:902–911. 2005. View Article : Google Scholar : PubMed/NCBI

Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BA, Erpelinck C, van der Velden VH, Havermans M, Avellino R, van Lom K, et al: A single oncogenic enhancer rearrangement causes concomitant EVI-1 and GATA2 deregulation in leukemia. Cell. 157:369–381. 2014. View Article : Google Scholar

Lahortiga I, Vázquez I, Agirre X, Larrayoz MJ, Vizmanos JL, Gozzetti A, Calasanz MJ and Odero MD: Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements. Genes Chromosomes Cancer. 40:179–189. PubMed/NCBI

Matsuo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, Horibe K, Kodama K, Tokumasu M, Itoh H, et al: EVI-1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia. Haematologica. 99:e225–e227. 2014. View Article : Google Scholar : PubMed/NCBI

Goyama S and Kurokawa M: EVI-1 as a critical regulator of leukemic cells. Int J Hematol. 91:753–757. 2010. View Article : Google Scholar : PubMed/NCBI

Ito Y: Oncogenic potential of the RUNX gene family: ‘overview’. Oncogene. 23:4198–4208. 2004. View Article : Google Scholar : PubMed/NCBI

van Wijnen AJ, Stein GS, Gergen JP, Groner Y, Hiebert SW, Ito Y, Liu P, Neil JC, Ohki M and Speck N: Nomenclature for Runt-related (RUNX) proteins. Oncogene. 23:4209–4210. 2004. View Article : Google Scholar : PubMed/NCBI

Levanon D and Groner Y: Structure and regulated expression of mammalian RUNX genes. Oncogene. 23:4211–4219. 2004. View Article : Google Scholar : PubMed/NCBI

Durst KL and Hiebert SW: Role of RUNX family members in transcriptional repression and gene silencing. Oncogene. 23:4220–4224. 2004. View Article : Google Scholar : PubMed/NCBI

Cameron ER and Neil JC: The Runx genes: Lineage-specific oncogenes and tumor suppressors. Oncogene. 23:4308–4314. 2004. View Article : Google Scholar : PubMed/NCBI

Mitani K: Molecular mechanisms of leukemogenesis by AML1/ EVI-1. Oncogene. 23:4263–4269. 2004. View Article : Google Scholar : PubMed/NCBI

Palmer S, Brouillet JP, Kilbey A, Fulton R, Walker M, Crossley M and Bartholomew C: EVI-1 transforming and repressor activities are mediated by CtBP co-repressor proteins. J Biol Chem. 276:25834–25840. 2001. View Article : Google Scholar : PubMed/NCBI

Senyuk V, Chakraborty S, Mikhail FM, Zhao R, Chi Y and Nucifora G: The leukemia-associated transcription repressor AML1/MDS1/EVI-1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells. Oncogene. 21:3232–3240. 2002. View Article : Google Scholar : PubMed/NCBI

Chinnadurai G: CtBP, an unconventional transcriptional corepressor in development and oncogenesis. Mol Cell. 9:213–224. 2002. View Article : Google Scholar : PubMed/NCBI

Kahata K, Asaka M and Miyazono K: TGF-beta signaling and carcinogenesis. Nihon Rinsho. 63(Suppl 4): 549–554. 2005.(In Japanese).

Hirai H, Izutsu K, Kurokawa M and Mitani K: Oncogenic mechanisms of EVI-1 protein. Cancer Chemother Pharmacol. 48(Suppl 1): S35–S40. 2001. View Article : Google Scholar : PubMed/NCBI

Alliston T, Ko TC, Cao Y, Liang YY, Feng XH, Chang C and Derynck R: Repression of bone morphogenetic protein and activin-inducible transcription by EVI-1. J Biol Chem. 280:24227–24237. 2005. View Article : Google Scholar : PubMed/NCBI

Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K and Hirai H: The corepressor CtBP interacts with EVI-1 to repress transforming growth factor β signaling. Blood. 97:2815–2822. 2001. View Article : Google Scholar : PubMed/NCBI

Vinatzer U, Taplick J, Seiser C, Fonatsch C and Wieser R: The leukaemia-associated transcription factors EVI-1 and MDS1/ EVI-1 repress transcription and interact with histone deacetylase. Br J Haematol. 114:566–573. 2001. View Article : Google Scholar : PubMed/NCBI

Liu Y, Chen L, Ko TC, Fields AP and Thompson EA: EVI-1 is a survival factor which conveys resistance to both TGFbeta-and taxol-mediated cell death via PI3K/AKT. Oncogene. 25:3565–3575. 2006. View Article : Google Scholar : PubMed/NCBI

Kurokawa M, Mitani K, Yamagata T, Takahashi T, Izutsu K, Ogawa S, Moriguchi T, Nishida E, Yazaki Y and Hirai H: The EVI-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J. 19:2958–2968. 2000. View Article : Google Scholar : PubMed/NCBI

Tanaka T, Nishida J, Mitani K, Ogawa S, Yazaki Y and Hirai H: EVI-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain. J Biol Chem. 269:24020–24026. 1994.PubMed/NCBI

Zhang Y, Sicot G, Cui X, Vogel M, Wuertzer CA, Lezon-Geyda K, Wheeler J, Harki DA, Muzikar KA, Stolper DA, et al: Targeting a DNA binding motif of the EVI-1 protein by a pyrrole-imidazole polyamide. Biochemistry. 50:10431–10441. 2011. View Article : Google Scholar : PubMed/NCBI

Kilbey A, Stephens V and Bartholomew C: Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in EVI-1 transformed fibroblasts. Cell Growth Differ. 10:601–610. 1999.PubMed/NCBI

Karakaya K, Herbst F, Ball C, Glimm H, Krämer A and Löffler H: Overexpression of EVI-1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase. Cell Cycle. 11:3492–3503. 2012. View Article : Google Scholar : PubMed/NCBI

Pradhan AK, Mohapatra AD, Nayak KB and Chakraborty S: Acetylation of the proto-oncogene EVI-1 abrogates Bcl-xL promoter binding and induces apoptosis. PLoS One. 6:e253702011. View Article : Google Scholar

Vázquez I, Maicas M, Cervera J, Agirre X, Marin-Béjar O, Marcotegui N, Vicente C, Lahortiga I, Gomez-Benito M, Carranza C, et al: Down-regulation of EVI-1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Haematologica. 96:1448–1456. 2011. View Article : Google Scholar

White DJ, Unwin RD, Bindels E, Pierce A, Teng HY, Muter J, Greystoke B, Somerville TD, Griffiths J, Lovell S, et al: Phosphorylation of the leukemic oncoprotein EVI-1 on serine 196 modulates DNA binding, transcriptional repression and transforming ability. PLoS One. 8:e665102013. View Article : Google Scholar

Volkert S, Schnittger S, Zenger M, Kern W, Haferlach T and Haferlach C: Amplification of EVI-1 on cytogenetically cryptic double minutes as new mechanism for increased expression of EVI-1. Cancer Genet. 207:103–108. 2014. View Article : Google Scholar : PubMed/NCBI

Lugthart S, Figueroa ME, Bindels E, Skrabanek L, Valk PJ, Li Y, Meyer S, Erpelinck-Verschueren C, Greally J, Löwenberg B, et al: Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI-1. Blood. 117:234–241. 2011. View Article : Google Scholar :

Yoshimi A and Kurokawa M: EVI-1 forms a bridge between the epigenetic machinery and signaling pathways. Oncotarget. 2:575–586. 2011. View Article : Google Scholar : PubMed/NCBI

Maicas M, Vázquez I, Vicente C, García-Sánchez MA, Marcotegui N, Urquiza L, Calasanz MJ and Odero MD: Functional characterization of the promoter region of the human EVI-1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription. Oncogene. 32:2069–2078. 2013. View Article : Google Scholar

Vasyutina E, Boucas JM, Bloehdorn J, Aszyk C, Crispatzu G, Stiefelhagen M, Breuer A, Mayer P, Lengerke C, Döhner H, et al: The regulatory interaction of EVI-1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. Leukemia. 10:10382015.

Matsuo H, Goyama S, Kamikubo Y and Adachi S: The subtype-specific features of EVI-1 and PRDM16 in acute myeloid leukemia. Haematologica. 100:e116–e117. 2015. View Article : Google Scholar : PubMed/NCBI

Takahashi S: Epigenetic aberrations in myeloid malignancies (Review). Int J Mol Med. 32:532–538. 2013.PubMed/NCBI

Jo A, Mitani S, Shiba N, Hayashi Y, Hara Y, Takahashi H, Tsukimoto I, Tawa A, Horibe K, Tomizawa D, et al: High expression of EVI-1 and MEL1 is a compelling poor prognostic marker of pediatric AML. Leukemia. 29:1076–1083. 2015. View Article : Google Scholar : PubMed/NCBI

Lavallée VP, Gendron P, Lemieux S, D'Angelo G, Hébert J and Sauvageau G: EVI-1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations. Blood. 125:140–143. 2015. View Article : Google Scholar